Updates in the Treatment of Waldenström Macroglobulinemia

This article discusses the current treatment landscape and therapeutic strategies for Waldenström macroglobulinemia, the role of Bruton tyrosine kinase inhibitor therapies in WM, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.

Related Videos
Claire Roddie, MD
Guillermo Garcia-Manero, MD
Amer Zeidan, MBBS
Expert on DLBCL
Tycel Phillips, MD
Expert on ALL
Michael Andreeff, MD, PhD
Brian C. Ball, MD
Mitchell E. Horwitz, MD
Related Content

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

June 4th 2023

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

May 26th 2023

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

June 4th 2023

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

May 26th 2023

Nivolumab With AVD Confers PFS Benefit Vs Brentuximab Vedotin Plus AVD in Advanced-stage Hodgkin Lymphoma

June 4th 2023

Andreeff Sheds Light on the Evaluation of the E-selectin Antagonist Uproleselan in AML

May 29th 2023

Obe-cel Elicits 76% CR/CRi Rate, 97% MRD-Negativity Rate in Relapsed/Refractory B-ALL

June 2nd 2023

FDA Approval Insights: Omidubicel in Blood Cancers Requiring Transplant

May 15th 2023

ASCO 2023 Insights: ADCS, Next-Generation TKIs, and More Lead Data Pack Ahead of Annual Meeting

May 31st 2023

Quizartinib Garners Approval in Japan for Newly Diagnosed FLT3-ITD+ AML

May 26th 2023